Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Ming Peng

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Medical Oncology|November 25, 2021
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based studyTai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
American Journal of Cancer Research|October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorinYen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 2, 2024
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancerCheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, et al.
Cancers|February 25, 2023
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic CancerYung-Yeh Su, Nai-Jung Chiang, Yi-Hsin Yang, et al.
International Journal of Surgery (London, England)|June 10, 2023
Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas: an international multicenter cohort studyMunseok Choi, Shin-E Wang, Joon Seong Park, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|February 19, 2022
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorinTai-Jan Chiu, Shih-Hung Yang, Sz-Chi Chiu, et al.
Frontiers in Oncology|July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter StudyYung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitorsCho-Han Chiang, Cho-Hung Chiang, Chun-Yu Peng, et al.
Heart (British Cardiac Society)|November 9, 2022
Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancerCho-Han Chiang, Cho-Hung Chiang, Cho-Hsien Chiang, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Medical Oncology|November 25, 2021
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based studyTai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
American Journal of Cancer Research|October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorinYen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 2, 2024
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancerCheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, et al.
Cancers|February 25, 2023
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic CancerYung-Yeh Su, Nai-Jung Chiang, Yi-Hsin Yang, et al.
International Journal of Surgery (London, England)|June 10, 2023
Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas: an international multicenter cohort studyMunseok Choi, Shin-E Wang, Joon Seong Park, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|February 19, 2022
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorinTai-Jan Chiu, Shih-Hung Yang, Sz-Chi Chiu, et al.
Frontiers in Oncology|July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter StudyYung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitorsCho-Han Chiang, Cho-Hung Chiang, Chun-Yu Peng, et al.
Heart (British Cardiac Society)|November 9, 2022
Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancerCho-Han Chiang, Cho-Hung Chiang, Cho-Hsien Chiang, et al.
Pageof 5